I 
119TH CONGRESS 
1ST SESSION H. R. 4780 
To identify and take action against international trade practices of high 
income countries that unfairly exploit innovation by deviating from mar-
ket-based policies and unfairly exploit United States innovation, and 
for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
JULY 29, 2025 
Mr. ARRINGTON (for himself, Mr. BUCHANAN, Mr. FLEISCHMANN, Ms. 
TENNEY, and Mr. MURPHY) introduced the following bill; which was re-
ferred to the Committee on Ways and Means 
A BILL 
To identify and take action against international trade prac-
tices of high income countries that unfairly exploit inno-
vation by deviating from market-based policies and un-
fairly exploit United States innovation, and for other 
purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Use Sovereignty To 
reduce Rx Act’’ or the ‘‘USTRx Act’’. 
SEC. 2. FINDINGS; SENSE OF CONGRESS. 
(a) FINDINGS.—Congress finds the following: 
VerDate Sep 11 2014 
22:48 Jul 31, 2025
Jkt 059200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H4780.IH
H4780
ssavage on LAPJG3WLY3PROD with BILLS
(1) Pharmaceutical price controls in foreign 
markets distort global trade flows and competition 
by depressing the prices of innovative drugs and ex-
ploiting pharmaceutical innovations researched and 
developed in the United States. 
(2) By setting prices at levels that are not mar-
ket-based, such price controls undervalue the dis-
covery of new, innovative treatments, diminish op-
portunities and incentives for global innovation in 
new medicines, and threaten to restrict access to 
new treatments and cures for United States patients 
and consumers. 
(3) Recognizing these dynamics, it is critical 
that the United States use all available trade tools 
to address such free-riding to ensure that foreign 
government regulatory reimbursement regimes are 
transparent, provide procedural fairness, are non- 
discriminatory, and provide full market access to 
United States products. 
(b) SENSE OF CONGRESS.—It is the sense of Con-
gress that— 
(1) ensuring the security of innovative and af-
fordable healthcare is a top priority for Americans 
and for Congress; 
VerDate Sep 11 2014 
22:48 Jul 31, 2025
Jkt 059200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H4780.IH
H4780
ssavage on LAPJG3WLY3PROD with BILLS
(2) foreign government policies that mandate 
artificially low drug prices in foreign markets under-
mine this priority by reducing global incentives to in-
vest in the development of new medicines; 
(3) such exploitative behavior unfairly shifts the 
cost of developing new treatments to the United 
States and unduly relies on America’s patients and 
taxpayers to finance global pharmaceutical innova-
tion; and 
(4) safeguarding access to life-saving treat-
ments for American patients requires combating 
such behavior so that foreign countries pay their fair 
share of the costs associated with the development of 
new drugs. 
SEC. 3. CHIEF PHARMACEUTICAL TRADE NEGOTIATOR. 
(a) ESTABLISHMENT.—Section 141(b) of the Trade 
Act of 1974 (19 U.S.C. 2171(b)), is amended as follows: 
(1) In paragraph (2)— 
(A) in the first sentence, by inserting ‘‘one 
Chief Pharmaceutical Trade Negotiator,’’ after 
‘‘one Chief Agricultural Negotiator,’’; and 
(B) by inserting ‘‘the Chief Pharmaceutical 
Trade Negotiator,’’ after ‘‘the Chief Agricul-
tural Negotiator,’’ each place it appears. 
VerDate Sep 11 2014 
22:48 Jul 31, 2025
Jkt 059200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H4780.IH
H4780
ssavage on LAPJG3WLY3PROD with BILLS
(2) By adding at the end the following new 
paragraph: 
‘‘(7) The principal functions of the Chief Phar-
maceutical Trade Negotiator shall be to conduct 
trade negotiations, enforce trade agreements relating 
to United States pharmaceutical products, and take 
appropriate action to address acts, policies, or prac-
tices of high-income countries that have a significant 
adverse impact on the ability of United States phar-
maceutical manufacturers to enjoy full market ac-
cess. The Chief Pharmaceutical Trade Negotiator 
shall be a vigorous advocate on behalf of United 
States manufacturers and consumers of pharma-
ceutical products and shall perform such other func-
tions as the United States Trade Representative 
may direct. In carrying out such duties, the Chief 
Pharmaceutical Negotiator shall, as appropriate, 
consult or coordinate with the Chief Intellectual 
Property Negotiator.’’. 
(b) ANNUAL REPORT.— 
(1) LIST
OF
HIGH-INCOME
COUNTRIES.—The 
United States Trade Representative shall compile 
and annually update a list of each foreign country 
that is defined as ‘‘high-income’’ by the official sta-
VerDate Sep 11 2014 
22:48 Jul 31, 2025
Jkt 059200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H4780.IH
H4780
ssavage on LAPJG3WLY3PROD with BILLS
tistics of the International Bank for Reconstruction 
and Development of the World Bank. 
(2) REPORT REQUIRED.—With respect to each 
country included on the most recent list required 
under paragraph (1), the United States Trade Rep-
resentative, acting through the Chief Pharmaceutical 
Trade Negotiator, (as established pursuant to the 
amendments made by subsection (a)) shall annually 
submit to the Committee on Ways and Means of the 
House of Representatives and the Committee on Fi-
nance of the Senate and concurrently publish on a 
publicly available website of the United States Trade 
Representative a report that— 
(A) describes in detail the results of a re-
view of the acts, policies, and practices of such 
country relating to the trade in pharmaceutical 
products in the previous fiscal year; 
(B) determines whether such acts, policies, 
or practices— 
(i) are not developed and implemented 
in a fair, nondiscriminatory, and trans-
parent manner; 
(ii) are not market-based or do not 
appropriately recognize the value of inno-
vative medicines; 
VerDate Sep 11 2014 
22:48 Jul 31, 2025
Jkt 059200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H4780.IH
H4780
ssavage on LAPJG3WLY3PROD with BILLS
(iii) deny reciprocal market access for 
United States products; 
(iv) diminish incentives for innovation 
in a manner that delays, prevents, or oth-
erwise adversely impacts the introduction 
of new medicines in the United States; 
(v) violate or are inconsistent with the 
provisions of, or otherwise deny benefits to 
the United States under, any bilateral or 
multilateral trade agreement with such 
country; and 
(vi) are unjustifiable or impose a sig-
nificant burden or unreasonable or dis-
criminatory restriction on United States 
commerce with such country; and 
(C) describes the current status of any re-
sponsive actions taken by the United States 
with respect to acts, policies, or practices for 
which the United States Trade Representative 
has determined and included in any prior re-
port, pursuant to subparagraph (B), that the 
interests of the United States are harmed, in-
cluding responsive actions pursuant to title III 
of the Trade Act of 1974 (19 U.S.C. 2411 et 
seq.). 
VerDate Sep 11 2014 
22:48 Jul 31, 2025
Jkt 059200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H4780.IH
H4780
ssavage on LAPJG3WLY3PROD with BILLS
(c) RESPONSE
TO ADVERSE ACTIONS.—Not later 
than 30 days after the United States Trade Representa-
tive determines that an act, policy, or practice of a country 
included in the applicable list required under subsection 
(b)(1) meets any of the criteria described in subsection 
(b)(2)(B), the United States Trade Representative shall 
submit to Committee on Ways and Means of the House 
of Representatives and the Committee on Finance of the 
Senate a plan to respond to such adverse action, which 
may include initiating an investigation under chapter 1 
title III of the Trade Act of 1974 (19 U.S.C. 2411 et 
seq.), in accordance with section 302(b)(1) of such chap-
ter. 
Æ 
VerDate Sep 11 2014 
22:48 Jul 31, 2025
Jkt 059200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6301
E:\BILLS\H4780.IH
H4780
ssavage on LAPJG3WLY3PROD with BILLS